Results 111 to 120 of about 3,887,212 (164)

Correction: Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment. [PDF]

Arch Endocrinol Metab, 2022
europepmc   +1 more source

The efficacy of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. [PDF]

J Cancer Res Clin Oncol, 2020
Zhang J, Song Q, Cai L, Xie Y, Chen Y.
europepmc   +1 more source

PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) AND THE PITUITARY: SAFETY AND EFFICACY

Peptide receptor radionuclide therapy (PRRT) is an emerging and promising targeted treatment for aggressive pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas refractory to conventional therapies.
Francesco Ferraù, Salvatore Cannavò, Elena Sofia Blanca, Carla Paola Costa   +3 more
core   +1 more source

Editorial: Diagnosis, treatment and prognosis of neuroendocrine neoplasms with a focus on peptide receptor radionuclide therapy (PRRT). [PDF]

Front Endocrinol (Lausanne)
Spyroglou A, Holmager P, Alexandraki KI.
europepmc   +1 more source

Recommendations for selection, treatment, and follow-up in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors: a Delphi consensus from the Galician Multidisciplinary Group on Neuroendocrine and Endocrine Tumors (GGNET). [PDF]

Clin Transl Oncol
Martinez-Lago N, Cabezas Agricola JM, Anido Herranz U, Nogareda Seoane Z, Cousillas Castiñeiras A, Varela Ponte R, Fernández Catalina P, Abou Jokh Casas E, de Matías Leralta JM, Pubul Nuñez V.   +9 more
europepmc   +1 more source

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [PDF]

BMC Cancer
Puranik AD, Dev ID, Yadav S, Rangarajan V, Agrawal A, Basu S, Chaudhari VA, Ramaswamy A, Ostwal V, Bhandare MS, Shrikhande SV, Parghane RV, Bhargava P, Bal MM, Yadav S, Patkar S, Goel M, Purandare NC, Shah S, Choudhury S, Ghosh S, Venkatachalam M.   +21 more
europepmc   +1 more source

Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT). [PDF]

EJNMMI Phys, 2018
Chicheportiche A, Artoul F, Schwartz A, Grozinsky-Glasberg S, Meirovitz A, Gross DJ, Godefroy J.   +6 more
europepmc   +1 more source

¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence. [PDF]

Endocr Oncol
Shekhda KM, Armeni E, Xu Y, D'afflitto M, Hayes A, Mandair D, Yu D, Quigley AM, Navalkissoor S, Gnanasegaran G, Grossman AB, Caplin M, Toumpanakis C, Khoo B.   +13 more
europepmc   +1 more source

Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs). [PDF]

Theranostics
Baum RP, Wang P, Jakobsson V, Zhao T, Schuchardt C, Khong PL, Zhang J.   +6 more
europepmc   +1 more source

Comment on Lai et al. Liver Transplantation for the Cure of Neuroendocrine Liver Metastasis: A Systematic Review with Particular Attention to the Risk Factors of Death and Recurrence. <i>Biomedicines</i> 2024, <i>12</i>, 2419. [PDF]

Biomedicines
Dal Z, Erkan M.
europepmc   +1 more source